On the other hand, Itaconate acid has been shown to inhibit the progression of estrogen receptor-positive (ER+) breast cancers by reprogramming tumor biochemical pathways and inducing abnormal metabolism (55). The gene discussed is ESR1; the disease is breast carcinoma.